AKT1 and ovarian clear cell cancer: mTOR is a serine/threonine kinase and downstream effector of the AKT signaling pathway, which has also been shown to be a possible therapeutic target in both cisplatin-sensitive and cisplatin-resistant clear cell ovarian carcinoma [24,25].